Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors

Clinical Cancer Research

Volumn 4, Issue 8, 1998, Pages 1915-1919

  Sparreboom, Alex ^a   De Jonge, Maja J A ^a   Punt, Cornelis J A ^b   Nooter, Kees ^a   Loos, Walter J ^a   Porro, Maria Grazia ^c   Verweij, Jaap ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; MACROGOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DETERMINATION; DRUG DISPOSITION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; CAPSULES; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAVENOUS; INTESTINAL ABSORPTION; MIDDLE AGED; NEOPLASMS;

EID: 0031852757     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gerrits, C. J. H., De Jonge, M. J. A., Schellens, J. H. M., Stoter, G., and Verweij, J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br. J. Cancer, 76: 952-962, 1997.
2. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
3. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S-M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxy-lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-721, 1989.
4. Takimoto, C. H., and Arbuck, S. G. The camptothecins. In: B. A. Chapner, and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 463-488. Philadelphia: Lippincott-Raven Publishers, 1996.
5. Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C., Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer, D., and Kufe, D. A Phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res., 1: 269-276, 1995.
6. Dahut, W., Harold, N., Takimoto, C., Allegra, C., Chen, A., Hamilton, J. M., Arbuck, S., Sorensen, M., Grollman, F., Nakashima, H., Lieberman, R., Liang, M., Corse, W., and Grem, J. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J. Clin. Oncol., 14: 1236-1244, 1996.
7. Takimoto, C. H., Dahut, W., Marino, M. T., Nakashima, H., Liang, M. D., Harold, N., Lieberman, R., Arbuck, S. G., Band, R. A., Chen, A. P., Hamilton, M., Cantilena, L. R., Allegra, C. J., and Grem, J. L. Pharmacokinetics and pharmacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J. Clin. Oncol., 15: 1492-1501, 1997.
8. Eder, J. P., Supko, J. G., Lynch, T., Bryant, M., Vosburgh, E., Shulman, L. N., Xu, G., and Kufe, D. W. Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin. Cancer Res., 4: 317-324, 1998.
9. Liu, G., Franssen, E., Fitch, M. I., and Warner, E. Patient preferences for oral versus intravenous palliative chemotherapy. J. Clin. Oncol., 15: 110-115, 1997.
10. Pastori, A., Farao, M., Geroni, C., Porro, M. G., and Grandi, M. Antitumor activity of 9-aminocamptothecin (9ac) by s.c. and oral route. Proc. Am. Assoc. Cancer Res., 38: 18, 1997.
11. De Souza, P. L., Cooper, M. R., Imondi, A. R., and Myers, C. E. 9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin. Cancer Res., 3: 287-294, 1997.
12. Loos, W. J., Sparreboom, A., Verweij, J., Nooter, K., Stoter, G., and Schellens, J. H. M. Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Appl., 694: 435-441, 1997.
13. Pithavala, Y. K., Soria, I., and Zimmerman, C. L. Use of the deconvolution principle in the estimation of absorption and pre-systemic intestinal elimination of drugs. Drug. Metab. Dispos., 25: 1260-1265, 1997.
14. Rowland, M., and Tozer, T. N. Clinical Pharmacokinetics: Concepts and Applications, Ed. 3. Media, PA: Williams and Wilkins, 1995.
15. Schellens, J. H. M., Creemers, G. J., Beijnen, J. H., Rosing, H., De Boer-Dennert, M., McDonald, M., Davies, B., and Verweij, J. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br. J. Cancer, 73: 1268-1271, 1996.
16. Gerrits, C. J. H., Schellens, J. H. M., Creemers, G. J., Wissel, P. S., Planting, A. S. T., Pritchard, J. F., DePee, S., De Boer-Dennert, M., Harteveld, M., and Verweij, J. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor. Br. J. Cancer, 76: 946-951, 1997.
17. Stewart, C. F., Zamboni, W. C., Crom, W. R., and Houghton, P. J. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother. Pharmacol., 40: 259-265, 1997.
18. Mi, Z., Malak, H., and Burke, T. G. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry, 34: 13722-13728, 1995.
19. Mani, S., Iyer, L., Janisch, L., Wang, X., Fleming, G. F., Schilsky, R. L., and Ratain, M. J. Phase I and pharmacokinetic study of oral 9-aminocamptothecin (9-AC)(NSC-603071). Proc. Am. Soc. Clin. Oncol., 16: 201a, 1997.